NPRL2、Survivin在肝细胞肝癌中的表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2014.617

摘要/Abstract

摘要： 目的探究NPRL2、Survivin在肝细胞肝癌中的作用,两者间的关系及其与各临床指标间的联系。方法收集45例肝细胞肝癌患者的癌组织、癌旁组织及15例正常肝脏组织,采用免疫组织化学方法、实时荧光定量RT-PCR法检测NPRL2、Survivin在各组织中的表达。结果 NPRL2在肝癌组织中的表达低于其癌旁组织、正常肝脏组织(P<0.01),与肿瘤TNM分期有关(P<0.05)。Survivin在肝癌组织中的表达高于癌旁组织、正常肝脏组织(P<0.01),且与血清AFP浓度、TNM分期有关(P<0.05)。在正常肝脏组织和癌旁组织中,NPRL2、Survivin的表达差异无统计学意义(P>0.05)。Spearman等级相关分析结果表明,NPRL2、Survivin mRNA在肝癌组织中的表达呈负相关(r=-0.45, P<0.01)。结论在肝细胞肝癌中,NPRL2是肿瘤抑制基因,Survivin是癌基因,且两者表达呈负相关,共同参与了肿瘤的发生发展。

关键词: RT-PCR, Survivin, NPRL2, 肝细胞肝癌, 免疫组织化学

Abstract: Objective To investigate the expressions of NPRL2 and Survivin, and their association with the clinicopathologic parameters of hepatocellular carcinoma (HCC). Methods A total of 45 HCC tissues, paracancerous liver tissues and 15 normal liver tissues were collected. Expressions of NPRL2 and Survivin were determined with immunohistochemistry and RT-PCR methods. Results Compared with paracancerous liver tissues and normal liver tissues, HCC tissues had higher Survivin expression but lower NPRL2 expression (P<0.01), but no significant differences were found between paracancerous liver tissues and normal liver tissues (P>0.05). NPRL2 expression was significantly related to TNM stage (P<0.05). Survivin expression was associated with serum AFP concentration and TNM stage (P<0.05). By spearman relative analysis, there was significant correlation between NPRL2 mRNA and Survivin mRNA (r=-0.45, P<0.01). Conclusion In hepatocellular carcinoma, anti-oncogene NPRL2 was negatively related to oncogene Survivin. The two genes may play important roles in the occurrence and development of hepatocellular carcinoma.

Key words: NPRL2, Survivin, Immunohistochemistry, RT-PCR, Hepatocellular carcinoma

中图分类号:

R735.7

谷旭, 王夏青, 任万华, 秦成勇, 韩国庆. NPRL2、Survivin在肝细胞肝癌中的表达及其临床意义[J]. 山东大学学报（医学版）, 2015, 53(6): 68-72.

GU Xu, WANG Xiaqing, REN Wanhua, QIN Chengyong, HAN Guoqing. Expression and clinical significance of NPRL2 and Survivin in hepatocellular carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 68-72.

参考文献

[1] 陈万青, 张思维,郑荣寿, 等. 中国2009年恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2013, 22(1): 10-21. CHEN Wanqing, ZHANG Siwei, ZHENG Rongshou, et al. Report of cancer incidence and mortality in China, 2009[J]. China Cancer, 2013, 22(1): 10-21.
[2] Aravalli RN, Cressman EN, Steer CJ, et al. Cellular and molecular mechanisms of hepatocellular carcinoma: an update[J]. Arch Toxicol, 2013, 87(2): 227-247.
[3] Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium[J]. Cancer Res, 2000, 60(21): 6116-6133.
[4] Zabarovsky ER, Lerman MI, Minna JD, et al. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers[J]. Oncogene, 2002, 21(45): 6915-6935.
[5] Liu AY, Liu DG, Du YJ, et al. Relationship between tumor and peripheral blood NPRL2 mRNA levels in patients with colorectal adenoma and colorectal cancer[J]. Cancer Biol Ther, 2014, 15(5): 489-495.
[6] Ambrosini G, Adida C, Altieri DC, et al. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997, 3(8): 917-921.
[7] Kanwar JR, Kamalapuram SK, Kanwar RK, et al. Survivin signaling in clinical oncology: a multifaceted dragon[J]. Med Res Rev, 2013, 33(4): 765-789.
[8] Li T, Wang G. Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities[J]. Int J Mol Sci, 2014, 15(10):18856-18891.
[9] Kurata A, Katayama R, Watanabe T, et al. TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling[J]. Cancer Sci, 2008, 99(9): 1827-1834.
[10] Kanwar JR, Kamalapuram SK, Kanwar RK, et al. Targeting Survivin in cancer: the cell-signalling perspective[J]. Drug Discov Today, 2011, 16(11-12): 485-494.
[11] Li J, Wang F, Haraldson K, et al. Functional characterization of the candidate tumor suppressor gene NPRL2 /G21 located in 3p21.3C[J]. Cancer Res, 2004, 64(18):6438-6443.
[12] Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects[J]. Exp Lung Res, 2007, 33(6): 289-301.
[13] Economidou F, Tzortzaki EG, Schiza S, et al. Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions[J]. Oncol Rep, 2007, 18(6): 1507-1512.
[14] Otani S, Takeda S, Yamada S, et al. The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor[J]. Journal of Surgical Oncology, 2009, 100(5): 358-363.
[15] Ueda K, Kawashima H, Ohtani S, et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells[J]. Cancer Res, 2006, 66(19): 9682-9690.
[16] Jin Y, Chen J, Feng Z, et al. The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma[J]. Tumour Biol, 2014, 35(10): 9905-9910.
[17] Selemetjev S, Dencic TI, Marecko I, et al. Evaluation of Survivin expression and its prognostic value in papillary thyroid carcinoma[J]. Pathol Res Pract, 2014, 210(1): 30-34.
[18] Sun PL, Jin Y, Kim H, et al. Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma[J]. Virchows Arch, 2013, 463(3): 427-436.
[19] Garcia-Saez I, Lacroix FB, Blot D, et al. Structural characterization of HBXIP: the protein that interacts with the anti-apoptotic protein Survivin and the oncogenic viral protein HBx[J]. J Mol Biol, 2011, 405(2): 331-340.
[20] Dieterle AM, Böhler P, Keppeler H, et al. PDK1 controls upstream PI3K expression and PIP3 generation[J]. Oncogene, 2014, 33(23): 3043-3053.
[21] Serrano-López J, Serrano J, Figueroa V, et al. Cytoplasmic localization of wild-type Survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia[J]. Haematologica, 2013, 98(12): 1877-1885.

相关文章 15

[1]	黄方康瑞吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[2]	王琳琳孙美丽孙玉萍张楠刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[3]	聂思月,王震,孙靖宇,刘杰,李娟,魏小娟,路春晓,吕兴龑,王淑云,孙玉萍. ANGPTL5在人胃癌组织中的表达及临床意义[J]. 山东大学学报（医学版）, 2017, 55(8): 61-65.
[4]	王永强,张维全,孙启峰,董晓鹏,彭传亮,张媛,赵小刚. 细胞角蛋白14基因在非小细胞肺癌中的表达与意义[J]. 山东大学学报（医学版）, 2017, 55(3): 83-87.
[5]	张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[6]	刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.
[7]	岳倩倩,王新怡,杨志强,姜舒. 富血供肝脏转移瘤与肝细胞肝癌的能谱CT成像定量分析[J]. 山东大学学报（医学版）, 2016, 54(7): 50-55.
[8]	王成, 荣艳华, 沈余明,张国安. 正常皮肤与增生性瘢痕中Ⅰ型和Ⅲ型胶原的含量与比例[J]. 山东大学学报（医学版）, 2016, 54(11): 64-67.
[9]	李红霞, 董蕾, 姜炅, 王新阳. 酪酪肽对胰腺癌Miapaca-2细胞凋亡的影响[J]. 山东大学学报（医学版）, 2015, 53(12): 7-11.
[10]	张明超, 聂云天. CDK8与E-cad在子宫内膜癌的发生、发展中的表达意义[J]. 山东大学学报（医学版）, 2014, 52(S1): 12-13.
[11]	刘益民，杜鲁涛，王丽丽，蒋秀梅，李娟，曲爱林，王海燕，郑桂喜，张欣，杨咏梅，王传新. 膀胱癌患者血清microRNA检测中内参基因的筛选及验证[J]. 山东大学学报（医学版）, 2014, 52(5): 86-91.
[12]	吴金华1，杨细虎1，刘振中2，丁晓军1，许建辉1. 凋亡抑制因子Survivin在口腔鳞癌中的表达及其意义[J]. 山东大学学报（医学版）, 2014, 52(4): 89-92.
[13]	王化淳1,黄圣运2,谢红军1,刘文雷1,张捷3,张东升1,2. 蛋白酪氨酸磷酸酶SHP-2在口腔鳞状细胞癌中的表达及临床意义[J]. 山东大学学报（医学版）, 2014, 52(2): 82-85.
[14]	贾秋桦, 于斐. Tim-3 在不明原因复发性流产患者绒毛和蜕膜组织中的表达[J]. 山东大学学报（医学版）, 2014, 52(10): 81-85.
[15]	李恒1，李哲1，乔晓俊1，高爱琴2，张楠2. 中心体α-微管蛋白、P53蛋白及端粒酶在原发性肝癌中的表达及相关性[J]. 山东大学学报(医学版), 2013, 51(8): 74-77.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed